Physician profile
Bruce Skolnick
NPI 1700831831
$3,770.78
in general payments reported to CMS, 2019-2025
22 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $227 · 2021: $625 · 2022: $1,104 · 2023: $348 · 2024: $295 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $716.63 | 2019-2024 | Wolverine Coronary Cutting Balloon, Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $456.94 | 2019-2023 | |
| Edwards Lifesciences Corporation | $394.88 | 2022-2025 | |
| Medtronic, INC. | $312.10 | 2022-2025 | Onyx Frontier |
| Abiomed | $309.89 | 2019-2023 | Impella |
| Biotronik INC. | $257.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $241.65 | 2021-2023 | Verquvo |
| Amgen INC. | $161.16 | 2019-2022 | |
| Shockwave Medical, INC | $156.10 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $153.01 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $118.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $71.59 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $70.00 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $68.78 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $59.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $27.13 | 2019-2022 | |
| United Therapeutics Corporation | $18.17 | 2025 | Tyvaso |
| Medicure Pharma INC. | $14.38 | 2021 | |
| Esperion Therapeutics, INC. | $13.13 | 2020 | |
| Allergan, INC. | $12.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Skolnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.